Allergan Acquires Chase Pharmaceuticals
November 23, 2016
Allergan (Dublin Ireland) announced that it has completed the acquisition of Chase Pharmaceuticals Corporation (Washington, DC) - a clinical-stage biopharma company focused on the development of treatments for neurodegenerative disorders -in a deal potentially worth $1 billion.
In order to expand its CNS R&D pipeline and "build on [its] commitment to Alzheimer's Disease", Allergan acquired Chase for an upfront payment of $125 million and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201, and certain backup compounds.
As part of the deal, the British subsidiary of India's Cipla has sold its 16.7% stake in Chase Pharmaceuticals to Allergan.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
